Free Trial
NASDAQ:SKYE

Skye Bioscience Q1 2026 Earnings Results & Report

Skye Bioscience logo
$1.09 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.16 +0.07 (+6.06%)
As of 11/13/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Skye Bioscience missed analyst earnings expectations in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$2.56 versus the -$2.32 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Skye Bioscience EPS Results

Actual EPS
-$2.56
Consensus EPS
-$2.32
Beat/Miss
Missed by -$0.24
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skye Bioscience Q1 2026 Earnings FAQ

Skye Bioscience (NASDAQ:SKYE) reported earnings of -$2.56 per share for Q1 2026, missing the consensus estimate of -$2.32. The report was announced on Monday, May 11, 2026.

Skye Bioscience Earnings Headlines

Skye Bioscience (NASDAQ:SKYE) Stock Price Down 4.8% - Here's Why
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company developing medicines that target the endocannabinoid system. Its research focuses on cannabinoid receptor 1 (CB1), which is involved in metabolic and other physiological processes.

The company’s lead program is nimacimab, an antibody designed to inhibit CB1 activity outside the brain. Skye is investigating the candidate as a potential treatment for obesity and related metabolic conditions.

Skye has also developed SBI-100 ophthalmic emulsion, an experimental eye treatment studied for glaucoma and ocular hypertension. The company is based in San Diego, California, and has shifted its development focus toward nimacimab.

View Skye Bioscience Profile